文献速递前列腺癌

基于人群的基因组风险分布特征构建局限性前列腺癌临床-基因组预后新系统

Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-12-09

研究在GRID(n=50,891)和MUSIC-Decipher(n=1602)两个前瞻性人群登记中,用Decipher基因组分类器评估基因组风险,并将其与STAR-CAP临床病理风险整合。整合后10年前列腺癌特异性死亡和远处转移风险跨度很大,并导致显著的阶段重分类。提示基因组与临床病理风险整合可细化风险评估、辅助个体化治疗。

要点

  • Decipher基因组风险在STAR-CAP各分期中分布不均,支持整合评估。
  • 整合Decipher-STAR-CAP后,10年PCSM为0.1%–48.8%,DM为0.3%–72.9%。
  • 整合系统导致23.4%升期、45.6%降期至少一个分期。

核心结论

  • 基因组与临床病理风险整合可能实现更细化的前列腺癌风险评估并帮助个体化治疗考量。

研究设计与样本

  • 在两个多机构前瞻性人群登记中评估Decipher基因组分类器:GRID(n=50,891)和MUSIC-Decipher(n=1602)。

主要发现

  • GRID中Decipher低、中、高风险分别为50.2%、18.5%、31.4%,MUSIC中分别为48.0%、16.2%、35.8%。
  • GRID中位年龄68岁、中位PSA 6.2 ng/mL,MUSIC中位年龄66岁、中位PSA 10.5 ng/mL。
  • 整合临床-基因组风险后,10年PCSM估计范围为0.1%至48.8%,DM为0.3%至72.9%。
  • 整合Decipher-STAR-CAP系统导致显著分期重分类,包括23.4%升期和45.6%降期至少一个分期。

临床怎么用

  • 在局限性前列腺癌预后评估中,可考虑将Decipher基因组风险与STAR-CAP临床病理风险整合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Genomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions. MATERIALS AND METHODS: Genomic risk was assessed using the Decipher genomic classifier in two separate multi-institutional, prospectively collected population-based registries: (1) Decipher Genomics Resource for Intelligent Discovery (GRID) [n = 50,891] and (2) Michigan Urological Surgery Improvement Collaborative (MUSIC-Decipher) [n = 1602]. The primary endpoint was estimated prostate cancer-specific mortality (PCSM), and secondary endpoint was distant metastasis (DM). Marginal risk estimates provided by STAR-CAP were combined with hazard ratios of Decipher to calculate integrated risk estimates. RESULTS: Median age and PSA was 68 years and 6.2 ng/mL in GRID, and 66 years and 10.5 ng/mL in MUSIC. The GRID population had 50.2%, 18.5%, and 31.4% with low-, intermediate-, and high-Decipher risk, compared to 48.0%, 16.2%, and 35.8% in MUSIC. Decipher-based genomic risk varied across STAR-CAP stages in both registries. Estimates of 10-year PCSM (0.1% to 48.8%) and DM (0.3%-72.9%) varied widely after integration of clinical-genomic risk. Use of an integrated Decipher-STAR-CAP system led to significant stage reclassification, including 23.4% upstaging and 45.6% downstaging at least one stage. CONCLUSIONS: These findings suggest integration of genomic and clinicopathologic risk may lead to more nuanced risk assessment in prostate cancer and may help individualize treatment consideration.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Singhal U, Jiang R, Proudfoot JA, et al. Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 41366130. doi:10.1038/s41391-025-01062-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。